Tengion(OTC) TNGNQ

Tengion, Inc. is a biotechnology company focused on regenerative medicine, established in 2003 and headquartered in Winston-Salem, North Carolina. The company specializes in the discovery, development, and commercialization of advanced cellular therapeutic products, often referred to as "neo-organs."

Products and Services

• Neo-Kidney Augment aims to enhance kidney function in chronic kidney disease patients
• Neo-Urinary Conduit provides an alternative for urinary diversion post-bladder removal
• Intellectual property rights in tissue engineering technology

Growth Outlook

• Potential market for regenerative medicine is projected to grow significantly
• Advancements in neo-organ technology could lead to new treatment options
• Increased interest in biotechnology investments may enhance funding opportunities

Financial Highlights

• Recent quarterly net income reported at -$20.2 million
• Cash and cash equivalents totaled $5.7 million as of September 30, 2014
• Trailing twelve months (TTM) cash flow from operations was negative, indicating ongoing challenges

Tengion, Inc. has positioned itself in a niche market with its innovative approach to regenerative medicine. The company's focus on developing neo-organs addresses critical healthcare needs, particularly for patients with chronic conditions. Despite facing financial challenges, the potential for growth in the biotechnology sector remains significant. The advancements in regenerative therapies and the increasing interest from investors could provide a pathway for future development and funding. Investors may find the company's unique offerings and market potential worth considering as the landscape of healthcare continues to evolve.